Epizyme Inc

Epizyme is a clinical stage biopharmaceutical company that is focused on the treatment of cancer and other diseases through discovering, developing, and commercializing epigenetic medicines. The company is developing its primary product candidate, tazemetostat, an oral selective inhibitor of the EZH2 histone methyltransferase in a range of cancer types and settings, and developing the primary development candidate in its G9a program, EZM8266, for the treatment of sickle cell disease. The company also has a pipeline of drug discovery programs that target its other chromatin modifying proteins. These programs are directed to specific cancers, including both hematological malignancies and solid tumors.
  • TickerEPZM
  • ISINUS29428V1044
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Roundup for Covered Companies

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa

ICML Taz Abstract Doesn’t Change the Narrative

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Roundup for Covered Companies

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa

ICML Taz Abstract Doesn’t Change the Narrative

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch